Cargando…
Severe COVID-19: what have we learned with the immunopathogenesis?
The COVID-19 outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global major concern. In this review, we addressed a theoretical model on immunopathogenesis associated with severe COVID-19, based on the current literature of SARS-CoV-2 and other epidemic pat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506814/ https://www.ncbi.nlm.nih.gov/pubmed/32962761 http://dx.doi.org/10.1186/s42358-020-00151-7 |
_version_ | 1783585100310511616 |
---|---|
author | Bordallo, Bruno Bellas, Mozart Cortez, Arthur Fernandes Vieira, Matheus Pinheiro, Marcelo |
author_facet | Bordallo, Bruno Bellas, Mozart Cortez, Arthur Fernandes Vieira, Matheus Pinheiro, Marcelo |
author_sort | Bordallo, Bruno |
collection | PubMed |
description | The COVID-19 outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global major concern. In this review, we addressed a theoretical model on immunopathogenesis associated with severe COVID-19, based on the current literature of SARS-CoV-2 and other epidemic pathogenic coronaviruses, such as SARS and MERS. Several studies have suggested that immune dysregulation and hyperinflammatory response induced by SARS-CoV-2 are more involved in disease severity than the virus itself. Immune dysregulation due to COVID-19 is characterized by delayed and impaired interferon response, lymphocyte exhaustion and cytokine storm that ultimately lead to diffuse lung tissue damage and posterior thrombotic phenomena. Considering there is a lack of clinical evidence provided by randomized clinical trials, the knowledge about SARS-CoV-2 disease pathogenesis and immune response is a cornerstone to develop rationale-based clinical therapeutic strategies. In this narrative review, the authors aimed to describe the immunopathogenesis of severe forms of COVID-19. |
format | Online Article Text |
id | pubmed-7506814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75068142020-09-23 Severe COVID-19: what have we learned with the immunopathogenesis? Bordallo, Bruno Bellas, Mozart Cortez, Arthur Fernandes Vieira, Matheus Pinheiro, Marcelo Adv Rheumatol Review The COVID-19 outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global major concern. In this review, we addressed a theoretical model on immunopathogenesis associated with severe COVID-19, based on the current literature of SARS-CoV-2 and other epidemic pathogenic coronaviruses, such as SARS and MERS. Several studies have suggested that immune dysregulation and hyperinflammatory response induced by SARS-CoV-2 are more involved in disease severity than the virus itself. Immune dysregulation due to COVID-19 is characterized by delayed and impaired interferon response, lymphocyte exhaustion and cytokine storm that ultimately lead to diffuse lung tissue damage and posterior thrombotic phenomena. Considering there is a lack of clinical evidence provided by randomized clinical trials, the knowledge about SARS-CoV-2 disease pathogenesis and immune response is a cornerstone to develop rationale-based clinical therapeutic strategies. In this narrative review, the authors aimed to describe the immunopathogenesis of severe forms of COVID-19. BioMed Central 2020-09-22 2020 /pmc/articles/PMC7506814/ /pubmed/32962761 http://dx.doi.org/10.1186/s42358-020-00151-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Bordallo, Bruno Bellas, Mozart Cortez, Arthur Fernandes Vieira, Matheus Pinheiro, Marcelo Severe COVID-19: what have we learned with the immunopathogenesis? |
title | Severe COVID-19: what have we learned with the immunopathogenesis? |
title_full | Severe COVID-19: what have we learned with the immunopathogenesis? |
title_fullStr | Severe COVID-19: what have we learned with the immunopathogenesis? |
title_full_unstemmed | Severe COVID-19: what have we learned with the immunopathogenesis? |
title_short | Severe COVID-19: what have we learned with the immunopathogenesis? |
title_sort | severe covid-19: what have we learned with the immunopathogenesis? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506814/ https://www.ncbi.nlm.nih.gov/pubmed/32962761 http://dx.doi.org/10.1186/s42358-020-00151-7 |
work_keys_str_mv | AT bordallobruno severecovid19whathavewelearnedwiththeimmunopathogenesis AT bellasmozart severecovid19whathavewelearnedwiththeimmunopathogenesis AT cortezarthurfernandes severecovid19whathavewelearnedwiththeimmunopathogenesis AT vieiramatheus severecovid19whathavewelearnedwiththeimmunopathogenesis AT pinheiromarcelo severecovid19whathavewelearnedwiththeimmunopathogenesis |